Heute sollte doch der Kurs durch die Decke gehen, oder?
Stem Cell Innovations Files Patents Relating to Production of Human Motor Neurons and Progenitors; Cells May Be Useful in Therapies for ALS, Parkinson's, Multiple Sclerosis and Other Neurodegenerative Diseases
SCOTCH PLAINS, N.J.--(BUSINESS WIRE)--April 28, 2006--
Stem Cell Innovations, Inc. (OTCBB: SCLL) has filed a patent application protecting the differentiation of its proprietary human pluripotent stem cells (PCs) into neural progenitor cells and purified populations of motor neurons. These cells will initially be used in the Company's core drug discovery and toxicology platform. The Company is also exploring therapeutic applications of these cells.
Dr. James Kelly, CEO of Stem Cell Innovations, Inc. (SCI), stated, "These cells have significant potential in both drug discovery and cell therapies to treat diseases such as ALS, Parkinson's, Huntington's, Multiple Sclerosis, and Spinal Cord Injury. Obtaining and protecting neural progenitor cells, as well as purified populations of motor neurons from our PCs, is a significant step for the company." Kelly added, "We are already in discussions with companies that have expressed interest in these cells."
Stem Cell Innovations is actively seeking to make its PC cells widely available to universities and other not-for-profit institutions to rapidly advance the potential of the cells for the benefit of people and the Company.
About Stem Cell Innovations
Stem Cell Innovations (SCI) is a cell biology company with offices in New Jersey, Houston, TX and Leiden, the Netherlands. SCI has developed and protected a unique pluripotent stem cell called the PC(TM). PCs have great potential in that they can be differentiated into virtually all cell types, and qualify for federal funding since PCs are not subject to the restrictions in National Institutes of Health funding imposed on ES cells. The PC program expands on the Company's currently marketed C3A human liver cell-based toxicology offerings.
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.
If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the differences could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
For more information about SCI, visit the company's Web site at: www.stemcellinnovations.com
Source: Stem Cell Innovations, Inc.
Und die ist von vor etwa 2 Wochen
Stem Cell Innovations Makes Their Human Embryonic Germ Cell Platform Commercially Available in Europe
CHICAGO, IL -- (MARKET WIRE) -- 04/12/06 -- At Bio2006 Stem Cell Innovations, Inc. (OTC BB: SCLL) announced today that the Company will commercialize their proprietary platform of human pluripotent stem cells in Europe through their newly established European R & D facility in Leiden, the Netherlands.
CEO Dr. James Kelly recently disclosed that SCI has produced multiple lines of human pluripotent stem cells. These cell lines are able to maintain their undifferentiated state and normal chromosome complement. The cells are produced without feeder layers (xenofree). The company is able to efficiently develop multiple lines, the first step in creating banks of cells that can be matched to patients in cell therapies.
To be able to serve the European market and to make the cells available to both scientists in Academia and the European Pharma and Biotech industry, SCI will produce stem cell lines in Leiden as well as in Houston, Texas.
About Stem Cell Innovations, Inc.
Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies, which is based in Houston, Texas, is a cell biology company. It utilizes its proprietary C3A human liver cell line in the field of drug discovery and toxicology testing and is also engaged in the development and production of its proprietary PC(TM) pluripotent stem cells. These human cell-based disease models create a platform for the discovery, testing and development of all therapeutic modalities including small molecules, cell-based therapeutics, small interfering RNAs and antibodies.
www.stemcellinnovations.com
This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects," "intends," "believes," "may," "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.
If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the differences could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.
Contact USA:
Dr. James H. Kelly
Chief Executive Officer
T +1 281 679 7900
Contact Europe:
Emmie van Halder
Business Development
M +31 6 53 202 105
T +31 70 322 8050
Ellen de Waal
PR & Corporate Communications
M +31 6 54 711 703
T +31 70 356 1534
